biotech

Pfizer Considers the Sales of its Consumer Healthcare Business

Pfizer Considers the Sales of its Consumer Healthcare Business

On Tuesday, Pfizer Inc. (NYSE: PFE), the pharmaceutical giant, said that it is considering the sale or spin-off of its consumer healthcare business, whose brands include lip balm Chapstick and painkiller Advil.The company’s consumer healthcare..

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..

Bayer Partnership with Start-Up in Agri Niche

Bayer Partnership with Start-Up in Agri Niche

A partnership has been announced between German company Bayer and a biotech start-up based in Boston to enable crops to make their own fertilizer. The move which is expected to make waves in the agriculture sector will give substantial impetus to Bo..

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..

Merck Acquires Rigontec for $550 Million

Merck Acquires Rigontec for $550 Million

Merck & Co. Inc. (NYSE: MRK) announced today its acquisition of German biotech start-up, Rigontec for approximately €464 million or $550 million to further advance studies and research in cancer treatment development.Merck agreed to pay &eu..

Insmed Incorporated Shares Jumped More than 100% After Positive Clinical Trial Data

Insmed Incorporated Shares Jumped More than 100% After Positive Clinical Trial Data

Insmed Incorporated (NASDAQ: INSM) stock jumped about 113% on Tuesday, after the biopharmaceutical company announced top-line data from its Phase 3 CONVERT study.The company announced that the global CONVERT study met its primary endpoint of culture..

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..